SABCS 2020 | RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the RxPONDER study, a Phase III trial evaluating whether the Oncotype DX® test can be used to spare chemotherapy in women with node-positive early-stage breast cancer. In this study, over 5000 women with an Oncotype DX Breast Recurrence Score ® were enrolled, in postmenopausal women with a recurrence score of 0-25, there was no benefit from chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.
